There is nothing more important to a medtech company—nor more confusing and misunderstood—than its intellectual property. An effective patent counsel is essential to a company to help it clarify and protect its most valuable asset. Two medical device experts from the intellectual property law firm Knobbe Martens highlight what to look for in an IP attorney who understands and can negotiate the medtech patent jungle.
YaraGo EMR - An Ophthalmology Specific Software_pitchdeckShankar Yaragoppa
One of the most respected ophthalmology specific EHR. Has set the vision to assist quality eye care delivery across the globe and positioned to become "Worlds top rated ophthalmology EHR in the next 3 years"
The document is a worksheet from MediCoventures for evaluating the fundability of medical device companies and technologies. It provides guidance on key criteria to evaluate such as customer validation, market size, competition, intellectual property, technical and clinical feasibility, regulatory pathway, and reimbursement. Entrepreneurs are instructed to use the worksheet to score themselves on these criteria in order to objectively assess whether their idea is worth pursuing and fundable.
This document summarizes a conference on medical device and diagnostic intellectual property and patent strategy. The conference will bring together in-house counsel and attorneys from medical device and diagnostic companies to discuss clarifying recent case law, process changes, and industry trends impacting IP preservation and expansion. It will include presentations on the implications of recent Supreme Court cases, utilizing inter partes review proceedings, managing patent budgets, partnering with academic institutions, and interpreting indefiniteness. The goal is to provide strategies for companies to strengthen protection of existing and developing intellectual property.
This document discusses how life sciences companies can address challenges in the industry by adopting new technologies. It identifies trends putting pressure on companies, such as new regulations and shifting customer expectations. It then presents solutions that technology can provide: a new multi-channel commercial model to better engage customers; business agility through cloud-based platforms to accelerate innovation; and a focus on outcomes through data analytics and patient services to improve care. Adopting modern cloud technologies, the document argues, is key for companies to transform their business models and adapt to changes in the industry environment.
Stc384 team phoenix scenario analysis exec summary approval from ccmClaudia Chittim
The document provides an executive summary of a scenario analysis for a cancer detection device that is in early development. It discusses the current medical device industry landscape and various factors that could impact the industry in the future. The analysis identifies key variables like FDA approval process and adoption rates. Several potential scenarios are constructed based on combinations of assumptions for each variable. Scenario 9 is identified as optimal for the cancer detection device, involving a differentiated strategy, focus on a niche market, and a proprietary technology that integrates with existing platforms.
There are several key challenges to commercializing new medical devices:
1) New devices must prove they offer real benefits over existing options. 2) Securing funding from investors is difficult due to the high risks and costs involved. 3) Extensive testing is required, including clinical trials, to obtain regulatory approval, which is also an expensive process. 4) There is often a disconnect between academic researchers developing new technologies and the business communities needed to commercialize them. Initiatives like IDEA Labs aim to help bridge this gap.
YaraGo EMR - An Ophthalmology Specific Software_pitchdeckShankar Yaragoppa
One of the most respected ophthalmology specific EHR. Has set the vision to assist quality eye care delivery across the globe and positioned to become "Worlds top rated ophthalmology EHR in the next 3 years"
The document is a worksheet from MediCoventures for evaluating the fundability of medical device companies and technologies. It provides guidance on key criteria to evaluate such as customer validation, market size, competition, intellectual property, technical and clinical feasibility, regulatory pathway, and reimbursement. Entrepreneurs are instructed to use the worksheet to score themselves on these criteria in order to objectively assess whether their idea is worth pursuing and fundable.
This document summarizes a conference on medical device and diagnostic intellectual property and patent strategy. The conference will bring together in-house counsel and attorneys from medical device and diagnostic companies to discuss clarifying recent case law, process changes, and industry trends impacting IP preservation and expansion. It will include presentations on the implications of recent Supreme Court cases, utilizing inter partes review proceedings, managing patent budgets, partnering with academic institutions, and interpreting indefiniteness. The goal is to provide strategies for companies to strengthen protection of existing and developing intellectual property.
This document discusses how life sciences companies can address challenges in the industry by adopting new technologies. It identifies trends putting pressure on companies, such as new regulations and shifting customer expectations. It then presents solutions that technology can provide: a new multi-channel commercial model to better engage customers; business agility through cloud-based platforms to accelerate innovation; and a focus on outcomes through data analytics and patient services to improve care. Adopting modern cloud technologies, the document argues, is key for companies to transform their business models and adapt to changes in the industry environment.
Stc384 team phoenix scenario analysis exec summary approval from ccmClaudia Chittim
The document provides an executive summary of a scenario analysis for a cancer detection device that is in early development. It discusses the current medical device industry landscape and various factors that could impact the industry in the future. The analysis identifies key variables like FDA approval process and adoption rates. Several potential scenarios are constructed based on combinations of assumptions for each variable. Scenario 9 is identified as optimal for the cancer detection device, involving a differentiated strategy, focus on a niche market, and a proprietary technology that integrates with existing platforms.
There are several key challenges to commercializing new medical devices:
1) New devices must prove they offer real benefits over existing options. 2) Securing funding from investors is difficult due to the high risks and costs involved. 3) Extensive testing is required, including clinical trials, to obtain regulatory approval, which is also an expensive process. 4) There is often a disconnect between academic researchers developing new technologies and the business communities needed to commercialize them. Initiatives like IDEA Labs aim to help bridge this gap.
The Kenya Pharmaceutical Regulatory Compliance Conference – July 25 – 26, 2017 at the Radisson Blu Hotel, Nairobi.
Compliance in the pharmaceutical industry is a critical issue, particularly in Kenya. Pharmaceutical companies across the globe face unparalleled challenges in the dynamically changing clinical, regulatory and business landscape. As regulatory scrutiny of the Pharmaceutical industry continues to intensify, compliance teams face increasingly complex challenges related to Legal Frameworks and Compliance, Effective Third Party Compliance Strategies, Best Practice Compliance Strategies, Internal Controls and Risk Management, Complexities of HCP interactions.
The inaugural edition of the Kenya Pharmaceutical Regulatory Compliance Conference will provide a venue for industry experts, policymakers, manufacturers, distributors, retailers and inventors to discuss and debate the challenges they face as well as explore new strategies.
The document provides information about an upcoming conference on pharmaceutical regulatory compliance in Kenya.
The conference will provide a venue for industry experts, policymakers, manufacturers, distributors, retailers and inventors to discuss challenges in the dynamically changing pharmaceutical landscape and explore new strategies. It will feature presentations, panels, workshops and exhibitions.
The event aims to bring together stakeholders in the pharmaceutical industry to address issues of regulatory compliance and engage on strengthening the regulatory framework in Kenya. Non-compliance poses risks to public health and undermines industry credibility. The conference organizers hope it will facilitate industry cooperation on regulatory best practices.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
This document discusses challenges and potential solutions related to market access for medical devices. Some key challenges include creating and communicating value to stakeholders, varied decision-making criteria across countries, technological evolution outpacing regulation updates, resource constraints in healthcare systems, lack of stakeholder engagement, and lack of evidence on economic value. Potential solutions proposed are focusing on health technology assessment processes, utilizing HTA groups as knowledge resources, reforming regulatory processes, increasing stakeholder involvement, using real-world data to drive device design and adoption, and effectively communicating value to end-users. Future trends may include increased combination products that integrate drugs, devices and/or biologics.
This document discusses challenges and potential solutions related to market access for medical devices. Some key challenges include creating and communicating value to stakeholders, varied decision-making criteria across countries, technological evolution outpacing regulatory updates, resource constraints in healthcare systems, lack of stakeholder engagement, and lack of evidence on economic value. Potential solutions proposed are focusing on health technology assessment processes, utilizing HTA groups as resources, reforming regulatory processes, increasing stakeholder involvement, using real-world data to drive device design and adoption, and effectively communicating value to end-users. Future trends may include increased combination products that integrate drugs, devices and/or biologics.
Playing to win in the life science tools marketBill Kelly
For the last year, clients have repeatedly been asking us similar questions:
- What's the outlook for life science funding?
- What's the impact of large mergers on the competitive environment?
- Are the ways scientists purchase products changing?
- Do new technologies represent a threat or an opportunity?
BioInformatics LLC has decided to answer these questions in our latest multi-sponsor research report, Competitive Strategies in an Era of Consolidation & Disruptive Technologies. We will undertake a comprehensive assessment of the current state of the global life science through extensive interviews with market participants, industry observers, procurement specialists and a survey of more than a thousand scientific customers from all market segments.
The document discusses Mass CONNECT, a program that aims to leverage industry networks to advance translational research and bridge the "translation gap" between academic discoveries and early-stage commercial opportunities. The program provides mentoring, industry screening of technologies, and connections to proven industry advisors and networks to accelerate promising opportunities and increase the throughput of technologies out of academic offices. It describes the ideal profiles of technologies and investigators that would benefit from the program.
White Paper - Internet Marketing Strategies For The Medical Device Industryjerryme5
This is a White Paper that I wrote, while employed at Exemplum, that talks about various marketing strategies that medical device companies can use to leverage the Internet to market their products more effectivelty.
Speeding Towards Commercialization Gra 121808 Finalsecurbme
The document discusses commercialization services for emerging biotechnology developments and medical devices. It introduces Secure BioMed Evaluations and Lassiter & Associates, who have expertise in bringing medical devices to market. Their services include evaluating commercial feasibility, regulatory pathway analysis, manufacturing analysis, reimbursement support, market validation, and market sizing to help clients expedite the process of getting products to market.
2015_11_29 - Research - The Perfect Incision...Intuitive Surgical's Innovativ...Mansoor Elahi
The document discusses Intuitive Surgical, a leader in robotic surgical systems. It describes Intuitive Surgical's history and business model, focusing on its flagship Da Vinci Surgical System. The medical appliances industry is large and growing, though also competitive with high barriers to entry. Intuitive Surgical faces challenges adopting its innovative technology, but aims to continuously innovate, pursuing new applications for robotics in surgery.
The document discusses how life sciences companies can deliver value beyond traditional medications by leveraging digital technologies. It recommends that life sciences IT organizations 1) drive digital innovation through rapid projects, 2) enable on-demand digital services, and 3) provide personalized apps and digital assets. To achieve this, the document outlines several strategic themes and IT capabilities needed, including establishing fluid and hybrid IT operations to support two-speed organizations and abstracting systems management. The goal is to transform IT value chains into fully digital services management to promote new digital offerings for patients.
The document summarizes an introduction to the FDA Social Media Hearing (FDASM). It provides background on the purpose of the hearing, which is to get public input on how expanded web technologies can be used to promote medical products to healthcare professionals and consumers in a truthful manner, and on internet adverse event reporting. The main questions to be addressed at the hearing are about accountability, regulatory requirements for social media promotion, corrective information on third party sites, appropriate use of links, and adverse event reporting. Highlights from a previous forum on related issues are also summarized.
Asia Pacific Pharmaceutical & Medical Professionals LinkedIn Group poll results and discussion on "Where do you see the most commercial innovation happening over the next 12 months?"
The document discusses uncertainties in the structure of the U.S. medical device industry. It notes that the FDA's stance on approving new medical devices could lower barriers to entry or increase threats to new entrants. New innovations may fragment the industry as they increase choice and potentially lower prices. New endoscopic devices that do not integrate into existing platforms may reduce industry profits by increasing learning curves.
This document is a quarterly newsletter providing updates on the Philadelphia life science industry. It includes articles on key topics:
1. The first article discusses how to stay informed on key players and emerging companies in a disease area through regularly asking questions about clinical trials, publications, collaborations, regulatory approvals and company pipelines.
2. The second article describes how some health tech companies have found success innovating around changes in healthcare by targeting preventative care, shifting care to the home, using lean processes and collaborating in innovation hubs.
3. Other sections provide information on investment strategies, performance metrics for local biotech companies, acquisitions and a list of companies in an investment index.
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
This document is a letter submitted in response to a proposed rule from the Centers for Medicare & Medicaid Services regarding Medicare coverage of innovative medical devices designated as breakthrough by the FDA. The letter applauds the proposed rule, which would provide national Medicare coverage starting on the date of FDA market authorization for 4 years. This would help start-up medical device companies commercialize their products after FDA approval and avoid the "Valley of Death" period between approval and reimbursement when patients may go untreated and companies may fail financially. The letter urges CMS to finalize and implement the proposed rule, arguing it would benefit both patients and the medical device industry. It is signed by current and former executives, investors, and advisors in start-up medical
Auto-injectors: choosing the right path | Insight, issue 2Team Consulting Ltd
The auto-injector market is growing rapidly due to a shift towards self-administration of therapies and a need for product differentiation. Auto-injectors provide patients independence and convenience over traditional syringe administration. While auto-injectors offer benefits, pharmaceutical companies face a complex selection process in choosing a development path for their product. Key decisions include whether to develop a new device, use an off-the-shelf option, or license a technology. Proper upfront planning is important to define needs and requirements, assess development options and timelines, and ensure regulatory approval.
The 10 Most Influential Leaders in MedTech Companies 2020 September 2020Merry D'souza
The 10 most influential leaders in medtech companies 2020 september 2020; Insights Succcess has published Magazine on 10 Most Influential Leaders in MedTech Companies in the September 2020.
Partner Ben Anger discusses the latest developments and advanced strategies for PTAB practice, specifically focused on the petitioner side. Ben covers issues related to selecting the prior art, anticipation versus single-reference obviousness, motivation to combine, post-institution practice, and more.
More Related Content
Similar to Ten Skills Medical Device Companies Need from Their Patent Attorneys
The Kenya Pharmaceutical Regulatory Compliance Conference – July 25 – 26, 2017 at the Radisson Blu Hotel, Nairobi.
Compliance in the pharmaceutical industry is a critical issue, particularly in Kenya. Pharmaceutical companies across the globe face unparalleled challenges in the dynamically changing clinical, regulatory and business landscape. As regulatory scrutiny of the Pharmaceutical industry continues to intensify, compliance teams face increasingly complex challenges related to Legal Frameworks and Compliance, Effective Third Party Compliance Strategies, Best Practice Compliance Strategies, Internal Controls and Risk Management, Complexities of HCP interactions.
The inaugural edition of the Kenya Pharmaceutical Regulatory Compliance Conference will provide a venue for industry experts, policymakers, manufacturers, distributors, retailers and inventors to discuss and debate the challenges they face as well as explore new strategies.
The document provides information about an upcoming conference on pharmaceutical regulatory compliance in Kenya.
The conference will provide a venue for industry experts, policymakers, manufacturers, distributors, retailers and inventors to discuss challenges in the dynamically changing pharmaceutical landscape and explore new strategies. It will feature presentations, panels, workshops and exhibitions.
The event aims to bring together stakeholders in the pharmaceutical industry to address issues of regulatory compliance and engage on strengthening the regulatory framework in Kenya. Non-compliance poses risks to public health and undermines industry credibility. The conference organizers hope it will facilitate industry cooperation on regulatory best practices.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
This document discusses challenges and potential solutions related to market access for medical devices. Some key challenges include creating and communicating value to stakeholders, varied decision-making criteria across countries, technological evolution outpacing regulation updates, resource constraints in healthcare systems, lack of stakeholder engagement, and lack of evidence on economic value. Potential solutions proposed are focusing on health technology assessment processes, utilizing HTA groups as knowledge resources, reforming regulatory processes, increasing stakeholder involvement, using real-world data to drive device design and adoption, and effectively communicating value to end-users. Future trends may include increased combination products that integrate drugs, devices and/or biologics.
This document discusses challenges and potential solutions related to market access for medical devices. Some key challenges include creating and communicating value to stakeholders, varied decision-making criteria across countries, technological evolution outpacing regulatory updates, resource constraints in healthcare systems, lack of stakeholder engagement, and lack of evidence on economic value. Potential solutions proposed are focusing on health technology assessment processes, utilizing HTA groups as resources, reforming regulatory processes, increasing stakeholder involvement, using real-world data to drive device design and adoption, and effectively communicating value to end-users. Future trends may include increased combination products that integrate drugs, devices and/or biologics.
Playing to win in the life science tools marketBill Kelly
For the last year, clients have repeatedly been asking us similar questions:
- What's the outlook for life science funding?
- What's the impact of large mergers on the competitive environment?
- Are the ways scientists purchase products changing?
- Do new technologies represent a threat or an opportunity?
BioInformatics LLC has decided to answer these questions in our latest multi-sponsor research report, Competitive Strategies in an Era of Consolidation & Disruptive Technologies. We will undertake a comprehensive assessment of the current state of the global life science through extensive interviews with market participants, industry observers, procurement specialists and a survey of more than a thousand scientific customers from all market segments.
The document discusses Mass CONNECT, a program that aims to leverage industry networks to advance translational research and bridge the "translation gap" between academic discoveries and early-stage commercial opportunities. The program provides mentoring, industry screening of technologies, and connections to proven industry advisors and networks to accelerate promising opportunities and increase the throughput of technologies out of academic offices. It describes the ideal profiles of technologies and investigators that would benefit from the program.
White Paper - Internet Marketing Strategies For The Medical Device Industryjerryme5
This is a White Paper that I wrote, while employed at Exemplum, that talks about various marketing strategies that medical device companies can use to leverage the Internet to market their products more effectivelty.
Speeding Towards Commercialization Gra 121808 Finalsecurbme
The document discusses commercialization services for emerging biotechnology developments and medical devices. It introduces Secure BioMed Evaluations and Lassiter & Associates, who have expertise in bringing medical devices to market. Their services include evaluating commercial feasibility, regulatory pathway analysis, manufacturing analysis, reimbursement support, market validation, and market sizing to help clients expedite the process of getting products to market.
2015_11_29 - Research - The Perfect Incision...Intuitive Surgical's Innovativ...Mansoor Elahi
The document discusses Intuitive Surgical, a leader in robotic surgical systems. It describes Intuitive Surgical's history and business model, focusing on its flagship Da Vinci Surgical System. The medical appliances industry is large and growing, though also competitive with high barriers to entry. Intuitive Surgical faces challenges adopting its innovative technology, but aims to continuously innovate, pursuing new applications for robotics in surgery.
The document discusses how life sciences companies can deliver value beyond traditional medications by leveraging digital technologies. It recommends that life sciences IT organizations 1) drive digital innovation through rapid projects, 2) enable on-demand digital services, and 3) provide personalized apps and digital assets. To achieve this, the document outlines several strategic themes and IT capabilities needed, including establishing fluid and hybrid IT operations to support two-speed organizations and abstracting systems management. The goal is to transform IT value chains into fully digital services management to promote new digital offerings for patients.
The document summarizes an introduction to the FDA Social Media Hearing (FDASM). It provides background on the purpose of the hearing, which is to get public input on how expanded web technologies can be used to promote medical products to healthcare professionals and consumers in a truthful manner, and on internet adverse event reporting. The main questions to be addressed at the hearing are about accountability, regulatory requirements for social media promotion, corrective information on third party sites, appropriate use of links, and adverse event reporting. Highlights from a previous forum on related issues are also summarized.
Asia Pacific Pharmaceutical & Medical Professionals LinkedIn Group poll results and discussion on "Where do you see the most commercial innovation happening over the next 12 months?"
The document discusses uncertainties in the structure of the U.S. medical device industry. It notes that the FDA's stance on approving new medical devices could lower barriers to entry or increase threats to new entrants. New innovations may fragment the industry as they increase choice and potentially lower prices. New endoscopic devices that do not integrate into existing platforms may reduce industry profits by increasing learning curves.
This document is a quarterly newsletter providing updates on the Philadelphia life science industry. It includes articles on key topics:
1. The first article discusses how to stay informed on key players and emerging companies in a disease area through regularly asking questions about clinical trials, publications, collaborations, regulatory approvals and company pipelines.
2. The second article describes how some health tech companies have found success innovating around changes in healthcare by targeting preventative care, shifting care to the home, using lean processes and collaborating in innovation hubs.
3. Other sections provide information on investment strategies, performance metrics for local biotech companies, acquisitions and a list of companies in an investment index.
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
This document is a letter submitted in response to a proposed rule from the Centers for Medicare & Medicaid Services regarding Medicare coverage of innovative medical devices designated as breakthrough by the FDA. The letter applauds the proposed rule, which would provide national Medicare coverage starting on the date of FDA market authorization for 4 years. This would help start-up medical device companies commercialize their products after FDA approval and avoid the "Valley of Death" period between approval and reimbursement when patients may go untreated and companies may fail financially. The letter urges CMS to finalize and implement the proposed rule, arguing it would benefit both patients and the medical device industry. It is signed by current and former executives, investors, and advisors in start-up medical
Auto-injectors: choosing the right path | Insight, issue 2Team Consulting Ltd
The auto-injector market is growing rapidly due to a shift towards self-administration of therapies and a need for product differentiation. Auto-injectors provide patients independence and convenience over traditional syringe administration. While auto-injectors offer benefits, pharmaceutical companies face a complex selection process in choosing a development path for their product. Key decisions include whether to develop a new device, use an off-the-shelf option, or license a technology. Proper upfront planning is important to define needs and requirements, assess development options and timelines, and ensure regulatory approval.
The 10 Most Influential Leaders in MedTech Companies 2020 September 2020Merry D'souza
The 10 most influential leaders in medtech companies 2020 september 2020; Insights Succcess has published Magazine on 10 Most Influential Leaders in MedTech Companies in the September 2020.
Similar to Ten Skills Medical Device Companies Need from Their Patent Attorneys (20)
Partner Ben Anger discusses the latest developments and advanced strategies for PTAB practice, specifically focused on the petitioner side. Ben covers issues related to selecting the prior art, anticipation versus single-reference obviousness, motivation to combine, post-institution practice, and more.
Partners Susan Natland and Jessica Sganga discussed potential trademark and copyright issues in the emerging metaverse, including the surge in popularity of NFTs (non-fungible tokens) and how they may affect intellectual property protections. Get up-to-speed on the “hot” cases in this evolving area and get practical tips on how best to protect your intellectual property from infringement in this virtual space.
Speakers: Susan Natland, Jessica Sganga
Knobbe partners Jeff Van Hoosear (OC) Jason Jardine (SD) and associate Julia Hanson (SD) recently gave a presentation at San Diego Fashion week on intellectual property for designers and artists. The presentation explored what IP is, why it is important to designers, top 5 misconceptions, how to get a copyright, how to get a trademark and how to get a design patent.
Partner Mauricio Uribe continued the two-part, comprehensive discussion on responding to IP threats and assertions. The presentation focused on a more detailed exploration of the topic and strategic implications for various scenarios.
Speakers: Mauricio Uribe
This document discusses strategic considerations for intellectual property risk mitigation and responding to patent infringement threats and assertions. It provides an overview of types of patent infringement, including literal infringement which occurs when each element of a patented claim is identical in an allegedly infringing device or process. It also discusses doctrine of equivalents, contributory infringement, and induced infringement. The document outlines appropriate and limited defenses to patent infringement and notes statutes related to willfulness and enhanced damages. Factors courts consider for determining willfulness are also provided.
Partner Mauricio Uribe continued the two-part, comprehensive discussion on open-source software and third-party vendors. The presentation focused on a more detailed exploration of the topic and strategic implications for various scenarios.
Speakers: Mauricio Uribe
Partner Jason Gersting, Ph.D. moderated a panel of his peers in a discussion about learning how to identify the waves in current written description and enablement law and tips for smoothly riding them to expand, enhance and protect life sciences intellectual property rights. Panelists included Knobbe Martens partners Jessica Achtsam, Eric Furman, Ph.D., and Dan Altman.
Partner Mauricio Uribe kicked off a two-part, comprehensive discussion on open-source software and third-party vendors. The presentation served as an introduction to the topic and provided more general information.
Speakers: Mauricio Uribe
Partner Mauricio Uribe continued the two-part, comprehensive discussion on data privacy. The presentation focused on a more detailed exploration of the topic and strategic implications for various scenarios .
Speakers: Mauricio Uribe
Partner Mauricio Uribe kicked off a two-part, comprehensive discussion on data privacy. The presentation served as an introduction to the topic and provided more general information.
Speakers: Mauricio Uribe
Partners Mauricio Uribe and Vlad Lozan gave an informative presentation on design patent law in the United States. The partners provided best practices for filing and prosecuting design patents in the U.S. and techniques and strategies for including multiple design embodiments in design patent applications. They also discussed how to identify and protect visual elements in computer-related technologies and how to integrate design patents into a holistic intellectual property strategy.
Speakers: Mauricio Uribe, Vlad Lozan
Partners Melanie Seelig and Mauricio Uribe continued the two-part, comprehensive discussion on trade secrets. The presentation focused on a more detailed exploration of the topic and strategic implications for various scenarios .
Speakers: Melanie Seelig and Mauricio Uribe
Partners Melanie Seelig and Mauricio Uribe kicked off a two-part, comprehensive discussion on trade secrets. The presentation served as an introduction to the topic and provided more general information.
Speakers: Melanie Seelig and Mauricio Uribe
Partners Mauricio Uribe and Paul Stellman continued the two-part, comprehensive discussion of strategic planning for capturing and protecting intellectual property. The presentation focused on a more detailed exploration of the topic, diving into the best intellectual property portfolios and cost deferrable strategies to maximize intellectual property spend.
Speakers: Mauricio Uribe and Paul Stellmann
Partners Mauricio Uribe and Vlad Teplitskiy gave an informative presentation on strategic considerations for claim drafting electrical and telecommunications Inventions. The partners provided illustrative claim drafting examples and best practices for defining claim scope, as well as claim drafting strategies for avoiding or minimizing unintentional functional claiming.
Speakers: Mauricio Uribe, Vlad Teplitskiy
Partners Maria Stout and Paul Stellman kicked off a two-part, comprehensive discussion of strategic planning for capturing and protecting intellectual property. The presentation served as an introduction to the topic and provided more general information.
Speakers: Maria Stout and Paul Stellmann
Partners Melanie Seelig and Mauricio Uribe continued the two-part, comprehensive discussion of strategic considerations regarding employment and vendor agreements. The presentation focused on a more detailed exploration of managing employment and vendor agreements, follow-on agreements, and sample language and practical examples.
Speakers: Melanie Seelig and Mauricio Uribe
The webinar covered strategic considerations for key terms in employee and vendor agreements regarding intellectual property and restrictive covenants. It discussed defining the scope of work and assignments of ownership for intellectual property created. Restrictive covenants like non-compete clauses, non-solicitation, anti-poaching, and confidentiality were also covered. The presentation addressed terms regarding the duration of the agreements and obligations after termination.
This document discusses advanced claiming strategies for artificial intelligence and machine learning inventions. It provides an overview of machine learning and the minimal requirements for an algorithm to be considered machine learning. It also discusses best practices for drafting patent claims for machine learning inventions, including providing detailed descriptions of the technical underpinnings of the AI technology and step-by-step algorithms. The document gives examples of potential patentable subject matter for machine learning inventions, such as collecting or forming a data set, modifications to algorithms, and using machine learning processed data. It provides sample patent claims related to training a neural network, predicting device failures using state and configuration data, and characterizing user inputs using machine learning.
More from Knobbe Martens - Intellectual Property Law (20)
Pedal to the Court Understanding Your Rights after a Cycling Collision.pdfSunsetWestLegalGroup
The immediate step is an intelligent choice; don’t procrastinate. In the aftermath of the crash, taking care of yourself and taking quick steps can help you protect yourself from significant injuries. Make sure that you have collected the essential data and information.
Sangyun Lee, 'Why Korea's Merger Control Occasionally Fails: A Public Choice ...Sangyun Lee
Presentation slides for a session held on June 4, 2024, at Kyoto University. This presentation is based on the presenter’s recent paper, coauthored with Hwang Lee, Professor, Korea University, with the same title, published in the Journal of Business Administration & Law, Volume 34, No. 2 (April 2024). The paper, written in Korean, is available at <https://shorturl.at/GCWcI>.
Business law for the students of undergraduate level. The presentation contains the summary of all the chapters under the syllabus of State University, Contract Act, Sale of Goods Act, Negotiable Instrument Act, Partnership Act, Limited Liability Act, Consumer Protection Act.
Corporate Governance : Scope and Legal Frameworkdevaki57
CORPORATE GOVERNANCE
MEANING
Corporate Governance refers to the way in which companies are governed and to what purpose. It identifies who has power and accountability, and who makes decisions. It is, in essence, a toolkit that enables management and the board to deal more effectively with the challenges of running a company.
Receivership and liquidation Accounts
Being a Paper Presented at Business Recovery and Insolvency Practitioners Association of Nigeria (BRIPAN) on Friday, August 18, 2023.
सुप्रीम कोर्ट ने यह भी माना था कि मजिस्ट्रेट का यह कर्तव्य है कि वह सुनिश्चित करे कि अधिकारी पीएमएलए के तहत निर्धारित प्रक्रिया के साथ-साथ संवैधानिक सुरक्षा उपायों का भी उचित रूप से पालन करें।
Genocide in International Criminal Law.pptxMasoudZamani13
Excited to share insights from my recent presentation on genocide! 💡 In light of ongoing debates, it's crucial to delve into the nuances of this grave crime.
Ten Skills Medical Device Companies Need from Their Patent Attorneys
1. MEDTECHSTRATEGIST.COM
See page 11
DECEMBER 6, 2016
Vol.3, No.17
MARKET TRACK
Published by Innovation In Medtech,llc
START-UPS TO WATCH
LEVEL EX:
A Virtual Simulator Transforms
Medical Education and Helps
Device Companies
Mary Stuart, 46
ORTOWAY:
A Gentle, Hydraulic Device
Achieves Vertebral Distraction
for a Wide Range of Lumbar
Spine Procedures
Mary Stuart, 48
PERSPECTIVE
A Post-Election First Take
for Device Manufacturers
Wendy Diller, 4
DIGITAL HEALTH
THE “SMART HEALTHCARE”
REVOLUTION:
Can Digital Tools, Advanced
Biosensors, and Data Analytics
Transform Healthcare as We Know It?
Mary Thompson, 8
Opportunities and Challenges in the
Digital Health Arena: A Conversation with
John Gardner of Nokia Growth Partners, 18
Israeli Start-Ups Exemplify Global Digital
Health Effort, 22
SPINE
NASS 2016:
Robotics, Safer Imaging
Take Center Stage
Wendy Diller, 24
Putting ASCs on J&J’s Commercial Map, 30
OUTSIDE OPINION
TEN SKILLS
Medical Device Companies Need
from Their Patent Attorneys
Paul Conover & Curtis Huffmire, 42
MEDTECH INVESTING
PEPPERMINT VENTURES:
Making the Connection
Between Medtech and Digital
David Cassak, 32
Digital Health Annual
Global Financing History
3. DECEMBER 6, 2016
43OUTSIDE OPINION
Skillful patent attorneys steeped in
the patent law understand its logic
and the policies behind it, but they
recognize that their clients only need
to know and understand the particu-
lar principles of patent law that are
needed to make important business
decisions along the way. These at-
torneys find ways, with straightfor-
ward explanations and analogies, to
clearly convey the necessary legal un-
derstanding to their clients, without
veering off into irrelevant legal nu-
ances and without using legal jargon
or terminology that is unhelpful and
distracting. When a patent attorney’s
explanations of the law or technology
are clear to a client, they will prob-
ably be clear to the patent office and
to other attorneys and to potential in-
vestors or acquirers as well.
3Solid understanding of
medical technology
and ability to communicate
it simply
In the broadest sense, the job of
medical device patent attorneys is to
learn about and thoroughly under-
stand the cutting-edge technology in
a particular field of healthcare, deter-
mine how their client has improved it,
and then explain that technology and
improvements in ways that are under-
standable and persuasive. These skills
play a very important role in drafting
patent applications, convincing exam-
iners to grant patents, negotiating and
drafting licensing deals, and perform-
ing or defending diligence in acquisi-
tions and investments involving intel-
lectual property.
Background knowledge in a field is
always helpful, but it is not necessary
for patent attorneys to have deep ex-
perience in a particular medical tech-
nology in order to be qualified to work
in it. In fact, specialized knowledge of-
ten comes from representing another
company on the same type of prod-
ucts, which may create a conflict of
interest that can sometimes block the
most technically experienced patent
attorneys from taking on new work in
that specific area.
It is more critical for a patent attor-
ney to have a broad general under-
standing of medical technology and
the ability to quickly and efficiently as-
similate and understand the technical
underpinnings, the market trends, and
the improvements, and then, most im-
portantly—the ability to explain all of
these in understandable and relatable
ways, without becoming bogged down
in technical minutia.
4Frequent personal
interactions with
medical device patent
examiners
As with most things in business and
in life, personal interactions are near-
ly always more productive and more
persuasive than written communica-
tions. This is especially true in pros-
ecuting patent applications. Patent
examiners deal with a large amount of
dry technical information in special-
ized fields. Over time, the stream of
different patent applications probably
can run together in their minds. Per-
sonal interactions can help to make
a particular patent application stand
out. But surprisingly, many patent at-
torneys do not routinely conduct tele-
phone or in-person interviews with
patent examiners.
Personal interviews with patent ex-
aminers can be especially helpful in
medical device patent applications,
since an effective explanation of the
benefits of a medical invention can be
very compelling, involving the qual-
ity and longevity of life itself. Also, for
medical inventions, demonstrations of
prototypes interacting with diagrams
or models of anatomy can very effec-
tively dispel any misunderstandings
of the technology or refute an exam-
iner’s erroneous positions.
Perhaps most importantly, a person-
al interview creates personal account-
ability on the part of a patent exam-
iner to be reasonable. Skillful medical
device patent attorneys conduct per-
sonal interviews with patent examin-
ers as often as possible and develop
strategies for presenting the technol-
ogy and legal arguments in a convinc-
ing manner during the interviews. This
practice helps to build rapport and
credibility over time with the groups
of medical device examiners who they
work with on a continuing basis.
5Familiarity with
business stages of
medical companies
Medical device companies come in
all shapes and sizes. However, there
are some consistent aspects and stag-
es common to medical device com-
panies that make the industry unique
compared with other industries. Some
medical device companies quickly
advance from the start-up phase to
the funding phase to the acquisition
phase or, in rare cases these days, an
IPO. Others may have already devel-
oped into substantial companies with
specialized divisions. Along the way,
medical device companies are com-
monly dealing with a myriad of issues
including regulatory, reimbursement,
safety, product liability, research and
development, clinical trials, barriers to
entry, US versus foreign development
options, supply and distribution chan-
nels, and many other challenges facing
the medtech industry.
Patent strategy needs to take into
account the overall business objec-
tives, the stage of company develop-
ment, and the available IP budget in
view of these other pressing matters.
For example, at the start-up stage, the
importance of adequately protecting
key developments and establishing
5. DECEMBER 6, 2016
45OUTSIDE OPINION
8Provides you with
updates in patent law
regarding medical devices
The patent law in the US and for-
eign countries is in constant flux. The
US Congress has implemented many
wide-ranging changes to the patent
statutes within the last few years,
and the US Patent Office continually
introduces new programs aimed at
improving patent examination and
speed that provide new options for
expediting patent applications and
interacting with patent examiners.
In addition, the US patent-appeals
court and Supreme Court issue nu-
merous decisions each year that
create binding legal precedents. It is
therefore crucial for patent attorneys
to continually study these changes in
the law and to adjust their practices
and strategies to achieve the maxi-
mum benefits for their clients.
But how does a medical device
company know whether its patent
counsel is keeping up with the new
developments in the law? In some sit-
uations, it may be a good idea to ask
your patent counsel about his or her
approach to keeping up on the law,
especially if any past experiences may
suggest problems. However, in most
cases, it is abundantly clear when pat-
ent attorneys are diligent in learning
about legal changes and implement-
ing new strategies because they con-
tinually provide updates on changes
in the law to their clients in strategy
discussions and discuss new ways of
responding to those changes.
9Stable team of
qualified attorneys
Medical device companies are de-
veloping cutting edge systems and
products. Skilled patent attorneys
need to develop a strong understand-
ing of the prior art technologies and
the unique aspects of the company’s
offerings and strategies. It takes time
and effort to develop that level of
familiarity with the company, the
improvements, the prior art, and
the business landscape. Over time,
both senior and junior patent attor-
neys will develop specialized tech-
nical knowledge, experience with
patent examiners, and a deeper un-
derstanding of industry players that
will be important to representation
of the company. This institutional
knowledge is a very valuable asset
to the company, and increases effi-
ciency and effectiveness in the rep-
resentation.
Unfortunately, attorneys who be-
come very familiar with the com-
pany’s strategy and portfolio some-
times leave their firm for various
reasons. Life brings change, and
some changes cannot be avoided.
However, some firms have a dispro-
portionately high degree of turnover
in their attorney ranks. If turnover
is high over an extended period of
time, several new attorneys may
have to be brought up to speed,
which can reduce the efficiency and
effectiveness of the representation,
and some institutional knowledge
can be lost.
Skilled patent attorneys seek to de-
velop a stable team of qualified at-
torneys to serve their clients. Using a
team framework fosters the sharing
of critical information among team
members and allows for new attor-
neys to be brought up to speed more
quickly and efficiently. An experi-
enced team will be able to handle
turnover without losing critical insti-
tutional knowledge and will be flex-
ible to the needs of the company as
they change over time. Skilled patent
attorneys should be managing teams
that have earned the company’s trust
and be able to make adjustments in
staffing matters that do not adverse-
ly impact the company’s strategy.
10Law firm highly
regarded in medical
device community
The reputation of a patent law firm
in the medical device community
can be very important, especially
for medical device companies in the
start-up, investment or acquisition
phases. When a well-regarded pat-
ent law firm with long experience
in the medical device field has been
engaged to prosecute a company’s
patents or to navigate around other
patents in the field or to explain the
company’s positions regarding intel-
lectual property in due diligence, the
level of credibility for the company
increases and the natural skepticism
on the part of those reviewing the
company’s technology and assets
decreases.
As noted, the intellectual property
of a medical device company is usu-
ally its most valuable asset, and it
should be entrusted only to patent
attorneys whose practices reveal a
high level of skill and competence.
When a medical device company’s
intellectual property is solid and se-
cure, the prospects for investment
and market success for life-improv-
ing and life-saving technologies are
maximized. However, figuring out
how to select an effective guide for
this journey can be difficult, frustrat-
ing and expensive. Hopefully the
suggested skills outlined above will
help ease this process.
Paul Conover Curtis Huffmire
Paul Conover (Paul.Conover@knobbe.
com) and Curtis Huffmire (Curtis.
Huffmire@knobbe.com) are partners
at Knobbe Martens, an intellectual
property law firm with a large medical
device practice.